Evidence map›Paper›PMID 31736068›Full record

Trial reportInternational journal of cancer2020

Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.

Matti Lehtinen, Dan Apter, Tiina Eriksson, Katja Harjula, Mari Hokkanen, Tuomas Lehtinen, Kari Natunen, Silvia Damaso, Maaria Soila, Dan Bi and 1 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00534638 (Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00534638 phase4completednot on this map

Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

TypeinterventionalSponsorGlaxoSmithKlineRan2007 to 2014Enrolled34,412ConditionsInfections, PapillomavirusArmsCervarix, Engerix-B
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. The Prevalence of HSV, HHV-6, HPV andPathogens (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Matti LehtinenDepartment of Infections and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dan ApterVL-Medi, Helsinki, Finland.
Tiina ErikssonFaculty of Social Sciences, University of Tampere, Tampere, Finland.
Katja HarjulaFaculty of Social Sciences, University of Tampere, Tampere, Finland.
Mari HokkanenFaculty of Social Sciences, University of Tampere, Tampere, Finland.
Tuomas LehtinenDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Kari NatunenFaculty of Social Sciences, University of Tampere, Tampere, Finland.
Silvia DamasoGSK, Wavre, Belgium.
Maaria SoilaGSK, Espoo, Finland.
Dan BiGSK, Wavre, Belgium.ORCID 0000-0003-0426-4639
Frank StruyfGSK, Wavre, Belgium.
Tampere University · FIGlaxoSmithKline (Belgium) · BEGerman Cancer Research Center · DEGlaxosmithkline (Finland) · FIKarolinska Institutet · SEVL-Medi Oy (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied effectiveness of the AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine against human papillomavirus (HPV) oropharyngeal infections associated with the increase of head/neck cancers in western countries. All 38,631 resident adolescents from 1994 to 1995 birth cohorts of 33 Finnish communities were invited in this community-randomized trial (NCT00534638). During 2008-2009, 11,275 girls and 6,129 boys were enrolled in three arms of 11 communities each. In Arm A, 90% of vaccinated girls/boys, and in Arm B, 90% of vaccinated girls received AS04-HPV-16/18 vaccine. Other Arm A/B and all Arm C vaccinated participants received control vaccine. All Arm A participants and Arm B female participants were blinded to vaccine allocation. Oropharyngeal samples were analyzed from 4,871 18.5-year-old females who attended follow-up visit 3-6 years postvaccination. HPV DNA prevalence was determined by SPF-10 LiPA and Multiplex type-specific PCR. Total vaccine effectiveness (VE) was defined as relative reduction of oropharyngeal HPV prevalence in pooled Arms A/B HPV-vaccinated females vs. all Arm C females. VE against oropharyngeal HPV-16/18, HPV-31/45 and HPV-31/33/45 infections were 82.4% (95% confidence intervals [CI]: 47.3-94.1), 75.3% (95%CI: 12.7-93.0) and 69.9% (95% CI: 29.6-87.1), respectively. In conclusion, the AS04-HPV-16/18 vaccine showed effectiveness against vaccine and nonvaccine HPV-types oropharyngeal infections in adolescent females up to 6 years postvaccination.

Indexed as

AdolescentAdultAluminum HydroxideFemaleFinlandHuman papillomavirus 16Human papillomavirus 18HumansLipid AOropharyngeal NeoplasmsOropharynxPapillomavirus InfectionsPapillomavirus VaccinesPharyngeal DiseasesSeroepidemiologic StudiesYoung AdultAluminum HydroxideASO4 mixturehuman papillomavirus vaccine, L1 type 16, 18Lipid APapillomavirus Vaccineshuman papillomavirusoral infectionoropharyngeal cancervaccine effectiveness

Identifiers

PMID31736068
PMCPMC7318585
OpenAlexW2984096412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.